Baseline sampling [Regulatives / Guidelines]

posted by NK – India, 2019-06-26 07:25 (462 d 04:19 ago) – Posting: # 20360
Views: 2,045

Hello everyone,

I have a question with regards to FDA OGD guidance of Dihydroergotamine Nasal Spray" dated February 2019.

The guidance specified that "baseline corrected PK data of AUC and Cmax should be used for bio-equivalence calculation"

As per my understanding, Dihydroergotamine is neither endogenous nor available in the diet, then why baseline value is required?

If it is required, what should be baseline sampling time points (-1h or -30 min or -15 min ...)?

Thanks in advance.

Regards
NK


Edit: URL corrected. [Helmut]

Complete thread:

Activity
 Admin contact
21,087 posts in 4,398 threads, 1,468 registered users;
online 4 (0 registered, 4 guests [including 2 identified bots]).
Forum time: Wednesday 11:44 CEST (Europe/Vienna)

When puzzled, it never hurts to read the primary documents 
a rather simple and self-evident principle that has, nonetheless,
completely disappeared from large sectors
of the American experience.    Stephen Jay Gould

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5